Search This Blog

Wednesday, May 30, 2018

Gilead started at buy by Piper


Gilead assumed with an Overweight at Piper Jaffray. Piper Jaffray analyst Tyler Van Buren assumed coverage of Gilead Sciences (GILD) with an Overweight rating and $85 price target. The analyst, after speaking with management, has a “high level of conviction” that pricing for the hepatitis C virus franchise has finally stabilized. It is inconceivable that AbbVie (ABBV) will continue to be irrational on pricing, Van Buren tells investors in a research note.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.